This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Rnai Activity of Sirnas Modified with 2'-Aminoalkyl-Substituted Fluorinated Nucleobases

Jens Haas^a; Thea Mueller-Kuller^b; Stefan Klein^b; Joachim W. Engels^a Institute for Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany ^b Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Germany

To cite this Article Haas, Jens , Mueller-Kuller, Thea , Klein, Stefan and Engels, Joachim W.(2007) 'Rnai Activity of Sirnas Modified with 2'-Aminoalkyl-Substituted Fluorinated Nucleobases', Nucleosides, Nucleotides and Nucleic Acids, 26: 6, 865-868

To link to this Article: DOI: 10.1080/15257770701504033 URL: http://dx.doi.org/10.1080/15257770701504033

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Nucleosides, Nucleotides, and Nucleic Acids, 26:865-868, 2007

Copyright © Taylor & Francis Group, LLC ISSN: 1525-7770 print / 1532-2335 online DOI: 10.1080/15257770701504033



RNAi ACTIVITY OF SIRNAS MODIFIED WITH 2'-AMINOALKYL-SUBSTITUTED FLUORINATED NUCLEOBASES

Jens Haas \Box Institute for Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

Thea Mueller-Kuller and Stefan Klein

Universitätsklinikum Frankfurt am Main, Frankfurt am Main, Germany

Universitätsklinikum Frankfurt am Main, Germany

Joachim W. Engels \Box Institute for Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

□ We recently reported that a 1'-deoxy-1'-(4,6-difluoro-1H-benzimidazol-1-yl)-2'-(β-aminoethyl)-β-D-ribofuranose nucleoside appears to be a universal nucleoside which does not differentiate between the four natural nucleosides A, C, G, and U in duplexes. Moreover, ribozymes modified with this nucleoside analog showed a better or at least equal catalytic activity relative to Watson-Crick mismatches. Due to these data, we investigated the ability of this compound to tolerate Watson-Crick mismatches in order to avoid HIV escape mutations in RNA interference. The influence of this nucleoside analog on siRNA efficiency was analyzed with a proven siRNA targeting GFP.

Keywords RNAi; siRNA; universal nucleosides; 2'-modification

INTRODUCTION

According to literature it is well established that due to the high mutation rate of HIV-1 the virus can escape from RNAi-mediated inhibition. [2,3] However, due to the behavior of 1'-deoxy-1'-(4,6-difluoro-1H-benzimidazol-1-yl)-2'-(β -aminoethyl)- β -D-ribofuranose as a universal nucleoside we investigated, if an insertion of this compound into the antisense strand of a siRNA could keep the efficiency of RNAi mechanism by silencing the corresponding mRNA at a high level. Therefore we synthesized the phosphoroamidite of this compound and incorporated it into siRNA 21-mers. For all RNAi-assays we have chosen a siRNA which is targeted to

We would like to thank the "Sonderforschungsbereich 579" and the "Deutsche Forschungsgemeinschaft" for financial support.

Address correspondence to Joachim W. Engeles, Institute for Organic Chemistry and Chemical Biology, Johann Wolfgang Goethe University, Max-von-Laue-Str. 7, 60438 Frankfurt am Main, Germany. E-mail: joachim.engels@chemie.uni-frankfurt.de




FIGURE 1 Schematical illustration of used siRNA construct and its target sequence of eGFP mRNA. 2'- $(\beta$ -aminoethyl)-4,6-difluorobenzimidazole substituted nucleoside was inserted at positions 7 and 13 in the antisense strand. As a control, Watson-Crick mismatches were inserted at the same positions.

nucleotides 238–258 of eGFP mRNA.^[4] The eGFP served as target gene, which was stably expressed in HeLa cells. The siRNA knock-down efficiency was measured by real time TaqMan-PCR,^[5] thereby expression of eGFP was normalized to huGAPDH expression. Down regulation on eGFP protein level was confirmed via FACS analysis. To monitor transfection efficacy, the uptake of Cy5-labelled siRNA was measured by flow cytometry.

RESULTS AND DISCUSSION

Given that some Watson-Crick mismatch base pairs were tolerated in RNA interference, [6] we first investigated a Watson-Crick mismatch that

FIGURE 2 Synthetical pathway for the synthesis of 1'-deoxy-1'-(4,6-difluoro-1H-benzimidazol-1-yl)-2'-(β -aminoethyl)- β -D-ribofuranose.




FIGURE 3 Analysis of the mRNA downregulation of modified siRNAs via TaqMan-PCR. HeLa-GFP cells were transfected with the 2'-(β-aminoethyl)-4,6-difluorobenzimidazole modified siRNA (siMod) and the mismatch control (siMM). As a negative control a nonsilencing siRNA (siContr) and as a positive control the unmodified siRNA (siGFP) were used. The determiniation of the GFP/GAPDH ratio of the transfected cells occurred 24 h after transfection via quantitative TaqMan-PCR. Percentage GFP-mRNA expression is illustrated relating to the control. Error bars represent the standard deviation of average values.

leads to a significant loss in siRNA activity. Thus, point mutations were inserted at positions 5 to 8 in the antisense-strand of the siRNA targeting GFP (Figure 1). The point mutation at position 7 ($G\rightarrow C$) was 6-fold less active in mRNA silencing compared to the unmodified control (data not shown). We tested if an insertion of 1'-deoxy-1'-(4,6-difluoro-1H-benzimidazol-1-yl)-2'-(β -aminoethyl)- β -D-ribofuranose on this position into the antisense strand of the siRNA could enhance its efficiency compared to the siRNA containing the Watson-Crick mismatch.

The synthesis of the protected phosphoroamidite of 1'-deoxy-1'-(4,6-difluoro-1H-benzimidazol-1-yl)-2'-(β -aminoethyl)- β -p-ribofuranose, shown in Figure 2, is described in detail elsewhere by Kloepffer and Engels.^[1]

The siRNA containing the universal nucleoside at pos. 7 in the antisense strand was analyzed for silencing activity by TaqMan-PCR and compared to the mismatch siRNA (Figure 3).

The modified siRNA showed a 71% higher silencing activity than the siRNA containing the C:C mismatch at the same position. However, another siRNA antisense strand with incorporated universal nucleoside at position 13 showed a significant decrease of silencing activity (data not shown).

These data suggest that an incorporation of 2'-(β -aminoethyl)-4,6-difluorobenzimidazole substituted nucleoside may increase the silencing activity in appearance of possible Watson-Crick mismatches.

REFERENCES

- Klöpffer, A.E.; Engels, J.W. Synthesis of 2'-aminoalkyl substituted fluorinated nucleobases and their influence on the kinetic properties of hammerhead ribozymes. *ChemBioChem* 2004, 5, 100–109.
- Boden, D.; Pusch, O.; Lee, F.; Tucker, L.; Ramratnam, B. Human immunodeficiency virus type 1 escape from RNA interference. *J. Virol.* 2003, 77, 11531–11535.
- Westerhout, E.M.; Ooms, M.; Vink, M.; Das A.; Berkhout, B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. *Nucleic Acids Res.* 2005, 33, 796–804.
- 4. Chiu Y.; Rana, T. siRNA function in RNAi: A chemical modification analysis. RNA 2003, 9, 1034–1048.
- Ikeda,Y.; Collins, M.K.L.; Radcliffe, P.A.; Mitrophanous, K.A.; Takeuchi, Y. Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Ther. 2002, 9, 932–938.
- Du, Q.; Thonberg, H.; Wang, J.; Wahlestedt, C.; Liang, Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. *Nucleic Acids Res.* 2005, 33, 1671– 1677.